167 related articles for article (PubMed ID: 14696561)
1. Atazanavir: clinical use.
Bartlett JG
Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
[No Abstract] [Full Text] [Related]
2. Drug profile: atazanavir (Reyataz, ATV).
Pham PA
Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
[No Abstract] [Full Text] [Related]
3. [New data on atazanavir/r]].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
[No Abstract] [Full Text] [Related]
4. Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
TreatmentUpdate; 2008 Mar; 20(2):7-8. PubMed ID: 18661646
[No Abstract] [Full Text] [Related]
5. Atazanavir: the advent of a new generation of more convenient protease inhibitors.
Barreiro P; Rendón A; Rodríguez-Nóvoa S; Soriano V
HIV Clin Trials; 2005; 6(1):50-61. PubMed ID: 15765311
[TBL] [Abstract][Full Text] [Related]
6. [HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():52. PubMed ID: 25026859
[No Abstract] [Full Text] [Related]
7. An unusual case of HIV virologic failure during treatment with boosted atazanavir.
Duncan A; Mills J
AIDS; 2013 May; 27(8):1361-2. PubMed ID: 23925384
[No Abstract] [Full Text] [Related]
8. Boosted Reyataz: 48-week results.
Huff B
GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
[No Abstract] [Full Text] [Related]
9. BMS-232632, a new protease inhibitor, is taken once daily.
Gaylord G
Posit Living; 2000 Jul; 9(6):22. PubMed ID: 12492017
[No Abstract] [Full Text] [Related]
10. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065
[No Abstract] [Full Text] [Related]
11. [Evidence-based therapeutic drug monitoring of atazanavir].
Solas C; Muret P;
Therapie; 2011; 66(3):213-9. PubMed ID: 21819805
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV agents. Atazanavir vs. Kaletra.
TreatmentUpdate; 2005; 17(1):3-4. PubMed ID: 17225314
[No Abstract] [Full Text] [Related]
13. Revised package insert for atazanavir.
Sax PE
AIDS Clin Care; 2008 Mar; 20(3):23. PubMed ID: 18399014
[No Abstract] [Full Text] [Related]
14. Atazanavir in children.
Prescrire Int; 2011; 20(118):177. PubMed ID: 21751749
[No Abstract] [Full Text] [Related]
15. Atazanavir: a novel HIV-1 protease inhibitor.
Piliero PJ
Expert Opin Investig Drugs; 2002 Sep; 11(9):1295-301. PubMed ID: 12225250
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir: a novel inhibitor of HIV-protease in haemodialysis.
Izzedine H; Launay-Vacher V; Peytavin G; Valantin MA; Deray G
Nephrol Dial Transplant; 2005 Apr; 20(4):852-3. PubMed ID: 15772278
[No Abstract] [Full Text] [Related]
17. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047
[No Abstract] [Full Text] [Related]
18. Review of atazanavir: a novel HIV protease inhibitor.
Fuster D; Clotet B
Expert Opin Pharmacother; 2005 Aug; 6(9):1565-72. PubMed ID: 16086644
[TBL] [Abstract][Full Text] [Related]
19. Drug interactions. Kaletra and atazanavir.
TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
[No Abstract] [Full Text] [Related]
20. Report from the 13th retrovirus conference. Extending the role of atazanavir.
Feinberg J
AIDS Clin Care; 2006 Apr; 18(4):38. PubMed ID: 16718882
[No Abstract] [Full Text] [Related]
[Next] [New Search]
